Related references
Note: Only part of the references are listed.Discovering dominant tumor immune archetypes in a pan-cancer census
Alexis J. Combes et al.
CELL (2022)
An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy
Sarah Chan et al.
NATURE CANCER (2022)
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas
Zohreh Amoozgar et al.
NATURE COMMUNICATIONS (2021)
4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma
Hyung-Don Kim et al.
HEPATOLOGY (2020)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
Kimberley M. Heinhuis et al.
JAMA ONCOLOGY (2020)
Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms
Jean-Christophe Beltra et al.
IMMUNITY (2020)
Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
Ani S. Balmanoukian et al.
CLINICAL CANCER RESEARCH (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer
Wenting Liao et al.
CANCER CELL (2019)
GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma
Adriaan A. van Beek et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Rational design of anti-GITR-based combination immunotherapy
Roberta Zappasodi et al.
NATURE MEDICINE (2019)
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
Denarda Dangaj et al.
CANCER CELL (2019)
Characterization and Comparison of GITR Expression in Solid Tumors
Luis Vence et al.
CLINICAL CANCER RESEARCH (2019)
Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules
Guoying Zhou et al.
JOURNAL OF HEPATOLOGY (2019)
HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality
David M. Richards et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers
Chang Gon Kim et al.
SCIENCE IMMUNOLOGY (2019)
Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
Imran Siddiqui et al.
IMMUNITY (2019)
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
Thomas Duhen et al.
NATURE COMMUNICATIONS (2018)
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Yannick Simoni et al.
NATURE (2018)
Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects
Jonathan E. Schoenhals et al.
FRONTIERS IN IMMUNOLOGY (2018)
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid- induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors
Ben Tran et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8(+) T Cells
Fernando P. Canale et al.
CANCER RESEARCH (2018)
Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8(+) T cell dysfunction and maintain memory phenotype
Bei Wang et al.
SCIENCE IMMUNOLOGY (2018)
Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy
Ashley E. Mahne et al.
CANCER RESEARCH (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory
Nick M. Durham et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses
Lindsay K. Ward-Kavanagh et al.
IMMUNITY (2016)
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Takuro Saito et al.
NATURE MEDICINE (2016)
Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+ Regulatory T Cells Are Depleted
Young H. Kim et al.
JOURNAL OF IMMUNOLOGY (2015)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Enhanced CD8 T Cell Responses through GITR-Mediated Costimulation Resolve Chronic Viral Infection
Maria Fernanda Pascutti et al.
PLOS PATHOGENS (2015)
GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo
Alexander Pedroza-Gonzalez et al.
ONCOIMMUNOLOGY (2015)
Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice
Judith T. Murphy et al.
BLOOD (2014)
Anti-GITR Agonist Therapy Intrinsically Enhances CD8 T Cell Responses to Chronic Lymphocytic Choriomeningitis Virus (LCMV), Thereby Circumventing LCMV-Induced Downregulation of Costimulatory GITR Ligand on APC
Derek L. Clouthier et al.
JOURNAL OF IMMUNOLOGY (2014)
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
David A. Schaer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Activated tumor-infiltrating CD4+regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer
Alexander Pedroza-Gonzalez et al.
HEPATOLOGY (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability
David A. Schaer et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
Makoto Miyara et al.
IMMUNITY (2009)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Stimulation of CD25+CD4+regulatory T cells through GITR breaks immunological self-tolerance
J Shimizu et al.
NATURE IMMUNOLOGY (2002)
Share Paper
